Marek's Disease Virus

Overview and Taxonomy of Marek's Disease Virus

Marek’s disease virus (MDV) represents a paradigm of viral oncogenesis and pathogen evolution under anthropogenic selective pressures. Designated as Gallid alphaherpesvirus 2 (GaHV-2) within the genus Mardivirus, subfamily Alphaherpesvirinae, and family Herpesviridae, MDV is the etiological agent of Marek’s disease (MD), a highly contagious, lymphoproliferative disorder of domestic chickens (Gallus gallus domesticus) [1-3]. The World Organisation for Animal Health (WOAH) classifies MD as a notifiable disease, reflecting its profound economic impact on global poultry production, with annual losses estimated to exceed US $1–2 billion due to mortality, condemnation at slaughter, and diminished egg production [2, 11]. The virus is not zoonotic and poses no direct threat to human health; however, its study provides an invaluable natural model for herpesvirus-induced tumorigenesis and offers critical insights into the evolutionary arms race between pathogens and vaccine-driven immunity [1, 3].

Taxonomic Classification and Serotypic Diversity

The genus Mardivirus encompasses three distinct serotypes that differ markedly in their pathogenicity and genomic content. MDV serotype 1 (GaHV-2) includes all oncogenic, pathogenic strains, ranging from mildly virulent (mMDV) to the hypervirulent (hvMDV) and very virulent plus (vv+MDV) pathotypes that have emerged over the past six decades [2, 6, 9]. Serotype 2 (GaHV-3) comprises naturally non-oncogenic strains, such as SB-1 and 301B/1, which are utilized as bivalent vaccine components [4, 12]. Serotype 3, also known as Meleagrid alphaherpesvirus 1 (MeHV-1) or turkey herpesvirus (HVT), was first isolated from clinically normal turkeys by Witter et al. [4]. HVT is antigenically related to MDV but is non-pathogenic in both chickens and turkeys; it has been deployed globally as a monovalent vaccine since the early 1970s [4, 7]. This tripartite serotypic classification remains foundational, as cross-protection between serotypes is incomplete, and the emergence of hvMDV strains capable of overcoming HVT- and bivalent vaccine-induced immunity has necessitated the adoption of the serotype 1-based CVI988 (Rispens) vaccine [1, 8].

Genomic Architecture and Repeat Region Organization

The MDV genome is a linear, double-stranded DNA molecule of approximately 180 kilobase pairs, organized into a class E herpesvirus architecture comprising unique long (UL) and unique short (US) segments, each flanked by inverted repeat regions: the terminal repeat long (TRL) and internal repeat long (IRL) for the UL region, and the internal repeat short (IRS) and terminal repeat short (TRS) for the US region [11, 13]. This arrangement results in the presence of two copies of numerous critical genes, most notably the major oncogene Meq (Marek’s EcoRI-Q), which resides within the IRL/TRL repeats [11]. Vychodil et al. [11] demonstrated, using a series of recombinant MDV mutants, that both copies of the internal repeat region are essential for efficient in vivo replication and pathogenesis, while replication in cell culture remains unaffected. This finding underscores the functional significance of genomic redundancy for viral fitness within the natural host.

A unique genomic feature of MDV is the presence of telomeric repeat arrays (TMRs), identical in sequence to vertebrate telomeres (TTAGGG)n, at the termini of its linear genome [13]. These TMRs facilitate the integration of the MDV genome into host telomeres during latency, a process that is critical for the maintenance of the latent state, for efficient reactivation, and ultimately for tumor induction [13]. Furthermore, MDV encodes a viral telomerase RNA subunit (vTR) that shares 88% sequence identity with the chicken telomerase RNA (chTR) and is highly expressed throughout the viral life cycle [13]. The vTR enhances telomerase activity, thereby contributing to the immortalization of transformed T cells and the progression of lymphoma [13]. The interplay between TMR-mediated integration and vTR-driven telomere maintenance represents a sophisticated viral strategy to hijack host chromosome biology for persistent infection and oncogenesis.

Phylogenetic Structuring and Evolutionary Dynamics

Phylogenomic analyses have revealed substantial geographic structuring among MDV field strains. Trimpert et al. [6] performed a time-calibrated phylogeny based on complete genome sequences and demonstrated that virulent MDV strains emerged independently in North America and Eurasia, with these emergence events coinciding temporally with the widespread adoption of vaccination in the 1960s–1970s. The mean evolutionary rate of MDV was estimated at approximately 1.6 × 10⁻⁵ substitutions per site per year, a rate that is remarkably high for a double-stranded DNA virus and approaches that of some RNA viruses [6, 10]. Padhi and Parcells [10] specifically examined the Meq oncogene and found that it is evolving under strong positive selection, with a diversification rate comparable to RNA viruses. Strikingly, the decades-long use of vaccines did not reduce MDV genetic diversity; rather, it appears to have stimulated the emergence and maintenance of highly diverse field strains until a pronounced bottleneck occurred around 2004–2005, followed by a recovery in diversity by 2010 [10].

The connection between vaccination and virulence escalation is supported by extensive epidemiological and experimental evidence. Dunn et al. [9] sequenced 70 MDV genomes with known virulence phenotypes and identified a clear phylogenetic separation between low-, virulent-, and very virulent-plus strains, with multiple genes (including Meq, pp38, vIL-8, and ICP4) exhibiting mutations statistically associated with increased virulence. Importantly, highly virulent isolates collected from the same farms persisted over multiple years despite eradication attempts, suggesting that once introduced, these strains can become enzootic [9]. The recent characterization of seven newly isolated Chinese field strains by Liu et al. [1] revealed that four of these isolates, SDCW01, HNXZ05, HNSQ05, and HNSQ01, exhibited hypervirulence, causing up to 100% cumulative MD incidence and 86.7% mortality, while simultaneously overcoming the protective immunity conferred by current commercial vaccines (CVI988, HVT, and bivalent combinations) with protection indices as low as 28–50%. Such findings illustrate that the trajectory of MDV evolution continues unabated, with novel pathotypes eroding the efficacy of established control measures [1, 5].

Functional Paleogenomics and the Origins of Virulence

A breakthrough in understanding the evolutionary trajectory of MDV virulence came from the paleogenomic study by Fiddaman et al. [2], who successfully sequenced MDV genomes from archaeological chicken remains spanning the past 1,000 years. These ancient sequences were found to be basal to all modern MDV strains, and functional testing of the reconstructed ancestral Meq oncogene revealed that it was severely compromised in its ability to drive tumor formation compared to contemporary versions. Of the 49 viral genes that displayed evidence of positive selection in modern strains, the authors identified specific fixed genetic changes that collectively account for the dramatic increase in virulence observed over the last century [2]. This study demonstrates that MDV has been circulating in chicken populations for at least a millennium, but only during the intensification of poultry production in the 20th century, characterized by high-density rearing and universal vaccination, did the virus transition from a presumably mild pathogen to a highly lethal, oncogenic agent [2, 6]. These findings have profound implications for understanding the selective pressures that can drive virulence evolution in other economically important livestock pathogens and underscore the necessity of integrating ecological and evolutionary principles into disease management strategies.

Molecular Pathogenesis of Marek’s Disease Virus

The molecular pathogenesis of Marek’s disease virus (MDV) represents a paradigm of sophisticated host-virus co-evolution, wherein a once-mild pathogen has transformed into a hypervirulent, immunosuppressive, and oncogenic agent that imposes an estimated annual economic burden exceeding US$1 billion on the global poultry industry [1, 2]. The World Organisation for Animal Health (WOAH) classifies MD as a notifiable disease of significant economic consequence, underscoring the critical importance of understanding its molecular underpinnings. MDV, a prototypic Mardivirus within the Alphaherpesvirinae subfamily, orchestrates a complex, multi-phasic lifecycle, lytic replication, latency, and reactivation, that is inextricably linked to its capacity for immune evasion, cellular transformation, and tumor induction. The molecular engines driving this pathogenesis have recently been dissected with unprecedented resolution, revealing a network of viral proteins, non-coding RNAs, and host cell interactions that dictate virulence, transmission, and the failure of vaccinal immunity.

The Meq Oncoprotein: A Central Hub of Transformation and Virulence

At the heart of MDV oncogenesis lies the Meq (Marek’s EcoRI-Q) protein, a basic leucine zipper (bZIP) transcription factor that is the functional ortholog of the cellular Jun/Fos oncoproteins and is universally expressed in MDV-induced lymphomas [5, 10]. The molecular architecture of Meq is the primary determinant of strain virulence. Critically, functional paleogenomic studies have demonstrated that ancient MDV strains, isolated from archaeological chicken remains approximately 1,000 years old, harbored a meq gene that encoded a protein profoundly diminished in its capacity to drive tumor formation [2]. This directly implicates the positive selection and rapid evolution of the meq locus as the molecular driver of the virulence escalation observed over the last century [10].

Modern hypervirulent and very virulent plus (vv+) strains exhibit specific polymorphisms, insertions, and duplications within the C-terminal transactivation domain of Meq, such as the 59-amino-acid insertion characteristic of the L-Meq isoform [5, 24]. These alterations enhance Meq’s transactivation potential, allowing it to more potently activate cellular and viral promoters involved in cell cycle progression and anti-apoptosis [5]. Remarkably, while a deletion isoform (S-Meq) also shows increased transactivation in reporter assays, it paradoxically reduces overall viral pathogenicity, suggesting that Meq’s functions extend beyond simple transcriptional activation to include critical roles in the establishment of latency and the subversion of the host cell environment [5].

Meq exerts its oncogenic and pathogenic effects through a multifaceted molecular strategy. It physically interacts with the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), thereby activating the PI3K/Akt signaling pathway [23]. This activation is a pivotal mechanism by which infected cells are protected from apoptosis, ensuring a permissive environment for viral replication and the survival of transformed T-cells during early infection [23]. Furthermore, Meq, in concert with the viral telomerase RNA subunit (vTR), contributes to the induction of the unfolded protein response (UPR), a cellular stress pathway that, when modulated by vv+ strains, may facilitate tumor progression [27]. The breadth of Meq’s influence is also underscored by its genetic locus, which serves as a hotspot for the generation of viral circular RNAs (circRNAs). These non-coding molecules, generated through back-splicing of pre-mRNA, are highly expressed from the meq transcriptional unit and the latency-associated transcripts (LATs) during infection [14]. Although their exact functions in pathogenesis remain to be fully elucidated, their abundance and location within key virulence genes suggest they represent an additional, sophisticated layer of post-transcriptional regulation that may contribute to the establishment of latency or the modulation of the host immune response [14].

Immune Evasion: Antagonism of Intrinsic and Innate Defenses

The ability of MDV to replicate, establish latency, and ultimately cause tumors is predicated on its extensive arsenal of immune evasion strategies. The virus must overcome the host’s first line of defense, the type I interferon (IFN) response. MDV encodes at least two potent inhibitors of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) DNA-sensing pathway. The tegument protein VP23 counteracts this pathway by directly interacting with interferon regulatory factor 7 (IRF7), thereby blocking IRF7’s association with TANK-binding kinase 1 (TBK1) and preventing its phosphorylation and nuclear translocation [18]. This selectively suppresses IRF7 activation while leaving NF-κB signaling intact, representing a precise and efficient mechanism to dampen the IFN-β response [18].

Complementing VP23, the viral protein RLORF4 targets the alternative arm of the cGAS-STING pathway. RLORF4 binds directly to the Rel homology domains of the NF-κB subunits p65 and p50, physically preventing their translocation to the nucleus and thereby abrogating NF-κB-dependent transcription of IFN-β and other pro-inflammatory cytokines [26]. The deletion of RLORF4 from the MDV genome results in enhanced IFN-β production and reduced viral titers in vivo, confirming that this immune evasion function is a critical determinant of virulence [26]. This sophisticated dual-pronged attack, suppressing both the IRF7 and NF-κB pathways, effectively disarms the host’s primary innate antiviral response, allowing the virus to establish a foothold.

Beyond innate immunity, MDV has evolved mechanisms to manipulate the adaptive immune response, particularly through its impact on antigen presentation. The chicken major histocompatibility complex (MHC) is unusually potent in conferring genetic resistance or susceptibility to MD, with the B21 haplotype being notably resistant and B19 susceptible [15, 16]. Immunopeptidomics has revealed a profound molecular basis for this differential resistance. The dominantly expressed class II molecule from a resistant haplotype, BL2*02, presents an extremely restricted repertoire of viral peptides, predominantly sourced from only four viral genes [16]. This limited epitope presentation, coupled with the virus’s ability to evade or subvert T-cell responses, explains the strong MHC-linked genetic control of disease outcome. Vaccination, while protective, relies on activating cellular immunity, including cytotoxic γδ T cells and CD8+ αβ T cells. However, the virus actively suppresses the induction of MEQ-specific T-cell responses in genetically susceptible chickens, a deficit that is not corrected by vaccination, thereby identifying a critical immune correlate of susceptibility [15].

Metabolic Hijacking and Cellular Subversion

To fuel its replicative program, MDV orchestrates a profound rewiring of host cell metabolism, a hallmark shared with many oncogenic viruses. Metabolomic profiling of MDV-infected cells reveals a shift towards glutaminolysis and glycolysis [17]. The virus drives a state of “glutamine addiction,” wherein infected cells become reliant on glutamine catabolism to fuel the tricarboxylic acid (TCA) cycle and provide biosynthetic precursors [17]. While glycolysis is also essential for viral replication, its primary role appears to be biosynthetic rather than energetic. In contrast, MDV replication does not require fatty acid β-oxidation, as inhibition of carnitine palmitoyltransferase 1a does not impair viral replication [17]. This metabolic reprogramming ensures the availability of nucleotides, amino acids, and energy for rapid viral DNA synthesis and particle assembly, creating a cellular environment that mimics a pro-proliferative, cancer-like state even before the onset of transformation.

Furthermore, MDV manipulates fundamental cellular processes such as apoptosis and cell survival to its advantage. The early infection phase is characterized by a dramatic atrophy of primary lymphoid organs, the thymus and bursa of Fabricius, driven by distinct cellular mechanisms. In the thymus, apoptosis is a direct consequence of lytic infection, as the majority of apoptotic cells are themselves infected with MDV [19]. Conversely, in the bursa of Fabricius, apoptosis predominantly occurs in uninfected bystander B cells, triggered by a still-undefined paracrine mechanism, leading to a severe B-lymphopenia [19]. This dual-mode of immune destruction facilitates a transient but severe immunosuppression, creating a window of vulnerability for the virus to disseminate systemically.

The Role of Viral Non-Coding RNAs and Genome Architecture

MDV encodes a suite of small non-coding RNAs (miRNAs) that are critical for oncogenicity, most notably the MDV-miR-M4, an ortholog of the oncogenic cellular miRNA-155 [20, 22]. MDV-miR-M4 is essential for the induction of T-cell lymphomas; viruses lacking this miRNA are severely compromised in their ability to form tumors [22]. However, precise in situ editing of lymphoma-derived cell lines using CRISPR/Cas9 has demonstrated that MDV-miR-M4 is dispensable for the maintenance of the transformed state [22]. This distinction is biologically profound, as it suggests that the initiation of transformation is mechanistically distinct from its maintenance, and that once malignancy is established, the transformed cells may develop independence from the specific viral oncogenic driver that initiated the process.

The physical organization of the MDV genome itself is a key virulence determinant. The genome contains inverted repeat regions (IRL/IRS) that harbor many genes essential for pathogenesis. Mutant viruses lacking the entire internal repeat region (ΔIRLS) replicate normally in vitro but are severely attenuated in vivo, demonstrating that both copies of the repeat regions are required for efficient replication and tumor induction [11]. These repeat regions are also the sites of integration of the viral genome into host telomeres, a process mediated by viral telomeric repeats (TMR) identical to the host’s own chromosome ends. This integration is critical for maintaining latency and facilitating the long-term persistence of the virus [13].

Viral Synergy and the Path to Hypervirulence

The molecular pathogenesis of MDV is not an isolated event; its effects are amplified by co-infections with other avian viruses. Co-infection with reticuloendotheliosis virus (REV) is a common field occurrence that significantly exacerbates MDV pathogenesis, increasing mortality and tumor incidence while simultaneously reducing the efficacy of vaccines like CVI988 [21, 25]. Similarly, superinfection with avian leukosis virus subgroup J (ALV-J) leads to synergistic viral replication, with dual-infected cells showing accelerated and enhanced viral protein biosynthesis, more severe cytopathy, and increased expression of immunosuppressive cytokines such as IL-10 and TGF-β [28]. These findings have direct practical implications for disease control, as they suggest that the presence of other immunosuppressive pathogens in a flock can subvert vaccinal immunity and permit the emergence of hypervirulent MDV strains [1]. The continuous circulation of these hypervirulent variants, as documented in recent field isolates from China [1] and the increasing detection of vv+ pathotypes globally [12], signals that MDV is in a state of ongoing molecular evolution, driven by the selective pressure of imperfect vaccines and intensive farming practices [6, 29]. The FAO and WOAH recognize that without a fundamental understanding of these molecular mechanisms, the risk of further virulence escalation and vaccine breakthrough will remain a persistent threat.

Epidemiology and Global Distribution of Marek's Disease Virus

Marek’s disease virus (MDV) presents a paradigmatic case of pathogen emergence and virulence escalation driven by anthropogenic changes in livestock production. Its global distribution, economic impact, and epidemiological complexity are unparalleled among avian pathogens, afflicting poultry operations on every continent where chickens are raised. Understanding the epidemiological patterns of MDV requires a synthesis of historical paleogenomics, contemporary field surveillance, phylodynamic modeling, and an appreciation for the selective pressures exerted by vaccination and intensive farming practices.

Historical Origins and Phylogenomic Context

The evolutionary history of MDV, as revealed by ancient DNA analyses, places the virus in intimate association with chickens for at least a millennium. Sequencing of MDV genomes from archaeological chicken remains demonstrates that the virus was circulating well before the industrial intensification of poultry production [2]. Crucially, functional testing of the ancient Meq oncogene indicates that ancestral strains were likely incapable of driving the fulminant T-cell lymphomagenesis that characterizes modern infections [2]. This finding underscores that contemporary virulence is a recent evolutionary acquisition, largely confined to the past century. Phylogenomic reconstructions further reveal a clear geographical structuring of MDV lineages, with independent trajectories of virulence evolution in Eurasia and North America [6]. Time-calibrated phylogenies estimate a mean evolutionary rate of approximately 1.6 × 10⁻⁵ substitutions per site per year, a pace that is remarkably high for a double-stranded DNA herpesvirus and that approaches rates seen in some RNA viruses [6, 10]. This rapid evolutionary clock has allowed MDV to respond swiftly to novel selective pressures, most notably the introduction of live-attenuated vaccines in the 1970s.

Current Global Distribution and Pathotype Landscape

MDV is enzootic in virtually all poultry-producing regions of the world, with seroprevalence approaching 100% in unvaccinated or improperly vaccinated flocks. While the virus itself is ubiquitous, the distribution of pathotypes, ranging from mild (m) to virulent (v), very virulent (vv), and very virulent plus (vv+), varies geographically and temporally. In North America, longitudinal genomic surveillance of 70 field strains with known virulence has documented a clear separation of pathotypes along phylogenetic branches, with high-virulence isolates persisting on individual farms for years despite eradication attempts [9]. In Eurasia, particularly in China, the situation is even more acute. A 2023 study characterized seven newly isolated field strains from tumor-bearing chickens in vaccinated flocks; four of these isolates were classified as hypervirulent (HV-MDV), causing cumulative tumor incidences of 30%–63.3% and mortality rates of 60%–86.7% in experimental infections [1]. These HV-MDV variants demonstrated the ability to significantly overcome the protection conferred by current commercial vaccines, including CVI988 (Rispens), HVT, and bivalent combinations, with protection indices as low as 28% for the 814 vaccine strain [1]. This pattern of vaccine breakthrough is not confined to China. In Colombia, molecular characterization of a field isolate from a commercial layer farm revealed a Meq gene with 99% sequence identity to Asian vv+ strains, including hallmark substitutions such as P176A, P217A, and P233L in the proline-rich region [12]. Similarly, a retrospective study in Brazil identified a natural coinfection of MDV and reticuloendotheliosis virus (REV) in a backyard flock, representing the first molecular characterization of REV in South America and emphasizing the global reach of MDV [25]. The World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) have long recognized MDV as a pathogen of profound economic significance, with annual global losses estimated to exceed US$1 billion [2], a figure some analyses place at up to US$2 billion when including costs of vaccination, mortality, and condemnation at slaughter [11].

Economic Impact and Surveillance Imperatives

The economic burden of MDV is multifaceted, encompassing direct mortality, reduced weight gain, egg production losses, and carcass condemnation due to tumorous lesions. A modeling framework applied to commercial broiler farms in the United States quantified that between-flock variation in host susceptibility, shedding rate, and cleanout efficiency significantly influences virus dynamics, and that virus reintroduction occurs approximately once per month even in well-managed facilities [29]. These models underscore that MDV transmission is not stochastic but is driven by ecologically measurable parameters, providing a basis for evaluating the impact of farming practices and the potential consequences of further virulence evolution. Surveillance of MDV has been bolstered by the development of rapid, field-deployable diagnostic tools, such as real-time recombinase polymerase amplification (RPA) targeting the highly conserved Meq gene, which achieves a detection limit of 10² copies/μL and can distinguish MDV from other avian pathogens [33]. Additionally, the use of feather tips and poultry dust as non-invasive sampling materials has revolutionized monitoring efforts, as these matrices contain high titers of cell-free infectious virions shed from the feather follicle epithelium, the sole known site of productive, lytic replication and environmental release [34].

Evolutionary Drivers: Vaccination and Industrial Intensification

The escalation of MDV virulence is arguably the most well-documented example of vaccine-driven pathogen evolution in any host system. Following the widespread adoption of the first HVT vaccine in the 1970s, field strains rapidly evolved to overcome vaccine-induced immunity, necessitating the development of bivalent (HVT + SB-1) and subsequently the CVI988 (Rispens) vaccine [3, 6]. However, even the gold-standard CVI988 does not provide sterilizing immunity; it prevents clinical disease and tumor formation but permits replication and shedding of virulent field viruses, thereby maintaining selection for ever-higher virulence [1, 9]. Population genetic analyses of the meq oncogene have demonstrated that the decades-long use of vaccines did not reduce MDV genetic diversity but instead had a stimulating effect, with positive selection operating on multiple codons in the C-terminal transactivation domain [10]. Notably, a sharp decline in genetic diversity around 2004–2005 was followed by recovery by 2010, suggestive of a selective sweep driven by the emergence of a particularly fit vv+ lineage [10]. Functional studies confirm that insertions (e.g., L-Meq) and deletions (S-Meq) in the meq coding sequence enhance transactivation activity and directly modulate virulence, with L-Meq recombinants inducing the highest mortality and tumor incidence [5]. The precise genetic determinants of virulence, however, are polygenic; genome-wide association studies of US field strains have identified multiple genes, including those involved in immune evasion and replication, consistent with a complex trait architecture [9]. Importantly, the independent emergence of virulent viruses in Eurasia and North America appears to coincide approximately with the introduction of comprehensive vaccination programs on each continent [6], providing strong correlative evidence for vaccine-driven evolution.

Transmission Ecology and Environmental Persistence

MDV is transmitted horizontally via the respiratory route, with infection initiated by inhalation of cell-free virions present in feather dander and dust. The virus is exceptionally stable in the environment, remaining infectious in poultry house dust for months, which facilitates long-distance spread via fomites and personnel. The tegument protein pUL47 has been identified as an essential factor for bird-to-bird transmission; deletion of UL47 renders the virus replication-competent and virulent in individual hosts but completely abrogates horizontal spread, likely through its role in enhancing splicing and expression of glycoprotein gC (UL44) [31]. Once inhaled, MDV infects lung macrophages and B cells, initiating a cytolytic infection that leads to immunosuppression, followed by latency in CD4⁺ T cells and eventual neoplastic transformation [3, 7]. The early replication phase is associated with profound atrophy of the thymus and bursa of Fabricius, driven by distinct mechanisms: in the thymus, infected cells undergo apoptosis, while in the bursa, uninfected bystander B cells are lost through apoptosis and suppressed proliferation, resulting in severe B-lymphopenia [19]. This transient immunosuppression exacerbates susceptibility to secondary infections and may facilitate co-infections with other oncogenic retroviruses.

Host Range and Co-Infection Dynamics

The primary host for MDV is the domestic chicken (Gallus gallus domesticus), but the virus can infect other galliform and anseriform birds, including turkeys, quail, and pheasants, although clinical disease is typically less severe in these species. The nonpathogenic turkey herpesvirus (HVT, serotype 3), which is antigenically related to MDV, serves as a widely used vaccine vector and has been isolated from turkeys in both North America and Europe [4]. HVT does not cause disease in chickens but confers cross-protective immunity against MDV challenge, a property exploited in vaccine development [4]. Co-infections of MDV with other oncogenic viruses, such as reticuloendotheliosis virus (REV) and avian leukosis virus subgroup J (ALV-J), are increasingly recognized as significant modifiers of disease severity and epidemiology. In China, co-infection with MDV and REV increased mortality by 20% and tumor rates by 26.7% compared to MDV alone, while concurrently reducing the protective indices of CVI988 and 814 vaccines by as much as 33.3 points [21]. Mechanistically, MDV and ALV-J synergistically enhance viral replication at both RNA and protein levels, and upregulate immunosuppressive cytokines such as IL-10 and TGF-β, leading to more severe histopathological lesions and metastatic spread [28]. These interactions highlight the importance of considering the broader pathogen community when assessing MDV epidemiology and vaccine efficacy.

Pathotype Variation and the Ongoing Arms Race

The continuous circulation of MDV in vaccinated flocks, coupled with its capacity for rapid genetic change, ensures that the global distribution of pathotypes remains dynamic. In China, field MDV strains isolated between 2008 and 2010 exhibited characteristic mutations in Meq (four amino acid substitutions) and vIL-8 (two substitutions) that were considered unique to circulating Chinese strains [24]. By 2023, the emergence of HV-MDV variants with the ability to break through CVI988 and HVT protection has prompted urgent calls for next-generation vaccines [1]. Similarly, in the United States, high-virulence isolates have persisted on farms for years despite depopulation and disinfection, suggesting that environmental reservoirs or cryptic reintroduction may thwart eradication [9]. The dilemma facing the poultry industry is stark: as long as vaccines prevent clinical disease but permit replication, MDV will continue to evolve, and each new vaccine generation may temporarily restore control only to be overcome by more virulent variants [6, 10]. The only sustainable solutions likely involve a combination of improved vaccine strategies (e.g., deletion-mutant vaccines that block transmission [8], multivalent platforms, or CRISPR-based interventions [32]), enhanced biosecurity, and genetic selection for host resistance [30]. The urgent need for novel interventions is underscored by the fact that the global poultry industry continues to expand, and MDV remains a potent threat to food security and animal welfare across all continents.

Clinical Manifestations and Pathological Features of Marek's Disease

Marek’s disease (MD) represents one of the most economically devastating lymphoproliferative disorders in poultry, with global annual losses estimated to exceed USD 1 billion [2]. The disease is caused by Gallid alphaherpesvirus 2 (GaHV-2), an oncogenic alphaherpesvirus that induces a complex, multi-phasic pathology characterized by immunosuppression, neurological dysfunction, and the rapid onset of T-cell lymphomas [3, 7]. The clinical and pathological landscape of MD has evolved dramatically over the past century, mirroring the virus's steady escalation in virulence and its capacity to overcome vaccine-induced immunity [2, 6, 10]. This evolution has transformed a once-mild disease into a hyperacute syndrome in unvaccinated flocks, where mortality can exceed 90% [2]. The World Organisation for Animal Health (WOAH) recognizes MD as a disease of significant economic and trade importance, underscoring the need for a detailed understanding of its clinical and pathological presentation.

Temporal Progression and Clinical Syndromes

The clinical manifestations of MD are not static; they unfold in a predictable temporal sequence that correlates with the virus's transition through lytic, latent, and transforming phases of infection. The hallmark of the disease is its variability, ranging from subclinical immunosuppression to acute mortality, driven largely by the virulence of the infecting strain and the host's genetic background [9, 30].

Early Cytolytic Infection and Immunosuppression (Days 3–14 Post-Infection): The earliest clinical phase is dominated by a profound, transient immunosuppression. This is triggered by the lytic replication of MDV in primary lymphoid organs, specifically the bursa of Fabricius and the thymus, as well as in the spleen [19]. The virus initially targets B lymphocytes and macrophages, establishing a productive infection that leads to cell destruction. A defining pathological feature of this stage is the rapid and severe atrophy of the thymus and bursa of Fabricius [19]. Detailed histopathological analysis has revealed that the mechanisms of atrophy differ between these two organs. In the thymus, the loss of cellularity is primarily driven by apoptosis of infected cells. In stark contrast, the bursa of Fabricius exhibits a high level of apoptosis in uninfected bystander cells, coupled with a marked inhibition of B-cell proliferation [19]. This bursal insult leads to a severe B-lymphopenia in the peripheral blood during the first two weeks, which can serve as a non-invasive diagnostic indicator of early MDV infection [19]. Clinically, this phase may present only as a mild malaise or growth depression, but its consequence is a compromised immune system that leaves the bird susceptible to secondary bacterial, viral, or parasitic infections, a phenomenon frequently observed in field settings [3, 7].

Latency and Reactivation (Days 7–21 Post-Infection): Following the initial wave of lytic infection, the virus establishes latency, primarily within activated CD4+ T lymphocytes [7]. This phase is clinically silent in many birds. The switch from latency to reactivation is a critical juncture, controlled by a complex interplay between viral factors, such as the Meq oncoprotein and viral microRNAs (miRNAs), and host cellular factors, including the transcription factor NF-κB and the activity of the PI3K/Akt pathway, which is hijacked by Meq to promote cell survival [22, 23, 36]. Reactivation is thought to be triggered by immune stress and is essential for the transition to the proliferative, neoplastic phase [3].

Late Immunosuppression and Secondary Immunodeficiency: As the infection progresses, a state of severe, sustained immunosuppression emerges. This is not merely a consequence of the early lymphoid atrophy but results from active immune evasion strategies employed by MDV. The virus encodes multiple proteins that subvert host antiviral defenses. For instance, the VP23 tegument protein inhibits the cGAS-STING DNA-sensing pathway by blocking IRF7 activation, thereby dampening type I interferon (IFN) responses [18]. Similarly, the RLORF4 protein antagonizes NF-κB activation, further curtailing IFN-β production [26]. This sustained immune dysregulation leaves birds in a vulnerable state throughout the rearing period.

Neurological Manifestations (Variable Onset): One of the most recognizable classical presentations of MD is the neurological syndrome, resulting from inflammation and demyelination of peripheral nerves, most notably the sciatic nerve, brachial plexus, and vagus nerve [12, 38]. Clinically, this manifests as a progressive, asymmetric paralysis. Affected birds may exhibit a characteristic "spraddle-leg" posture, where one leg is extended forward and the other backward, drooping of the wing, or torticollis. However, in flocks infected with very virulent plus (vv+) strains, the classical neurological form has become less prominent, overshadowed by acute mortality and visceral tumor formation [3, 5].

Visceral Lymphoma and Neoplastic Phase (From 4 Weeks Post-Infection): The most economically significant and pathognomonic feature of MD is the formation of lymphomatous tumors. This proliferative phase is driven by the transformation of latently infected CD4+ T cells into neoplastic cells. The tumor formation is critically dependent on the viral oncogene meq, an ortholog of the cellular transcription factor c-jun [2, 5, 10]. The Meq protein, acting as a transcriptional regulator, activates a cascade of cellular genes that drive uncontrolled proliferation and inhibit apoptosis [5, 23]. The timing and incidence of tumor formation are highly strain-dependent. Hypervirulent MDV (HV-MDV) strains, such as those isolated from vaccinated flocks in China, can induce tumor incidences of 100% in susceptible birds, often with significant mortality within 67–73 days post-infection [1].

Grossly, tumors are firm, white to grayish, focal or multifocal nodules that can arise in virtually any visceral organ, but are most consistently found in the liver, spleen, kidney, ovary, proventriculus, heart, and lungs [1, 28, 38]. The World Organisation for Animal Health (WOAH) emphasizes that MD should be a differential diagnosis for any multi-visceral lymphoma in chickens. Hepatosplenomegaly is a consistent and striking feature, with the liver and spleen often enlarged multiple times their normal size [1]. Tumors can also infiltrate the skeletal muscle, skin (around feather follicles), and the intestinal tract [38]. Histologically, the tumors are composed of a diffuse, monomorphic population of pleomorphic, large lymphocytes, mostly CD4+ T cells, with a high mitotic index. These cells exhibit a characteristic "fried-egg" appearance in impression smears, with large, vesicular nuclei and prominent nucleoli [38]. Immunohistochemistry confirms the T-cell origin, with strong positivity for CD3 [38]. Notably, even in the face of advanced lymphoma, the birds often show concurrent severe atrophy of the thymus and bursa, underscoring the dual nature of the disease as both a neoplastic and an immunosuppressive condition [1].

Pathological Features of Key Organs and Tissues

While any organ can be affected, certain tissues present distinct and diagnostically crucial pathological features.

Skin and Feather Follicle Epithelium (FFE): The FFE is the only anatomical site where the virus completes its lytic cycle, producing large quantities of enveloped, cell-free infectious virions that are shed into the environment, making contaminated dust the primary route of transmission [31, 34]. This is a critical feature not seen in other herpesvirus infections. Infected FFE cells show degeneration, necrosis, and parakeratotic hyperkeratosis. The resultant skin lesions, often visible as raised, crusty lesions around feather follicles, are a key clinical sign in some forms of MD, particularly in older birds. The permissive nature of FFE cells is a direct reflection of the virus's tropism for differentiated epithelial cells [34]. The stability of MDV in the environment, facilitated by its association with dander and feather dust, is a primary reason for its ubiquity and the challenge of eradication.

Peripheral Nerves: The classic histologic lesion is a lymphomatous infiltration of the nerve, leading to a loss of myelin and axonal degeneration. The infiltrate is a mixture of neoplastic T cells and inflammatory cells. This can result in a grossly visible, significantly thickened, and edematous sciatic nerve, often with loss of the normal transverse striations. This pathological finding directly correlates with the clinical presentation of lameness and paralysis.

Lymphoid Organs (Bursa, Thymus, Spleen): As detailed, the bursa and thymus exhibit profound atrophy due to a combination of lytic infection, apoptosis, and suppression of cellular proliferation [19]. The thymus may be so severely reduced as to be difficult to locate at necropsy. The spleen, in contrast, is typically enlarged in the early stages due to proliferation of lymphocytes and macrophages, but in the later stages can be replaced by lymphomatous nodules.

Factors Influencing Clinical and Pathological Presentation

The diverse outcomes of MDV infection, ranging from subclinical infection to fulminant lymphoma, are modulated by at least four critical interacting factors: the virulence of the viral strain, the host's genetic susceptibility, the age and immunocompetence of the host at the time of infection, and the presence of co-infections.

Viral Pathotype: MDV strains are classified into a continuum of pathotypes, from mild (mMDV) to very virulent plus (vv+MDV). This pathotype is determined by the ability to cause disease in vaccinated birds. Virulence is genetically linked to polymorphisms in the meq gene, with vv+ strains consistently exhibiting specific amino acid substitutions (e.g., P176A, P217A, P233L) and insertions/deletions that enhance its transactivation activity and, consequently, oncogenicity [5, 12, 24]. As demonstrated by recent field isolates from China, hypervirulent strains (HV-MDV) can now overcome the protection afforded by even the most effective vaccines, such as CVI988 (Rispens), leading to 100% tumor incidence in challenged birds [1].

Host Genetic Resistance: The chicken major histocompatibility complex (MHC) is the single most potent genetic determinant of resistance or susceptibility [16, 30]. Chickens with the B21 MHC haplotype are highly resistant, while those with the B19 haplotype are highly susceptible [15]. The mechanism for this is now clearer: the dominantly expressed class II molecule in resistant birds (e.g., BL2*02) has a highly specific binding motif for viral antigens. Remarkably, it appears to present peptides from only a limited number of viral genes, explaining how such a complex virus can be controlled by a single MHC locus [16]. In addition to the MHC, genome-wide association studies (GWAS) have identified over 38 quantitative trait loci (QTL) on 19 chromosomes that contribute to resistance, highlighting the polygenic nature of host defense [30]. Resistant lines mount stronger, more sustained, and broader T-cell responses (including both αβ and γδ T cells) to key viral antigens like pp38 and Meq [15, 35, 37].

Co-infections: The clinical and pathological picture of MD is profoundly exacerbated by concurrent infections. Co-infection with reticuloendotheliosis virus (REV) or avian leukosis virus subgroup J (ALV-J) dramatically increases mortality, tumor incidence, and the severity of immunosuppression [21, 28]. This synergistic pathogenicity is driven by enhanced viral replication of both pathogens, likely due to the immunosuppressive environment created by MDV. In co-infected birds, the protective efficacy of MD vaccines can be significantly reduced, with protection indices dropping by as much as 33% [21].

Diagnostic Approaches for Marek's Disease Virus Infection

The diagnosis of Marek's disease virus (MDV) infection, caused by the oncogenic alphaherpesvirus Gallid herpesvirus 2 (GaHV-2), represents a multifaceted challenge that demands a sophisticated integration of clinical observation, gross pathology, histological examination, advanced molecular detection, serological surveillance, and increasingly, immunological profiling. The necessity for such a comprehensive diagnostic arsenal is underscored by the virus's complex lifecycle, its ability to induce a spectrum of pathologies ranging from immunosuppression and paralysis to rapid-onset T-cell lymphomas, and the continuous emergence of hypervirulent field strains capable of overcoming vaccine-induced protection [1, 3, 6]. As the World Organisation for Animal Health (WOAH) recognizes, Marek's disease (MD) is a disease of significant economic consequence, and accurate diagnosis is paramount for implementing effective control strategies and monitoring the evolutionary trajectory of the virus in both commercial and backyard poultry operations.

Clinical and Gross Pathological Assessment

The initial diagnostic suspicion for MDV infection is typically triggered by characteristic clinical signs and gross lesions observed during necropsy. Clinically, birds may present with progressive paralysis, most notably of the legs and wings, due to peripheral nerve infiltration by lymphoid cells, along with non-specific signs such as depression, weight loss, and pallor. However, the insidious nature of the infection, particularly in vaccinated flocks where clinical signs are often suppressed, means that diagnosis cannot rely on clinical presentation alone [12, 38]. Gross pathological examination remains a cornerstone of initial diagnosis. The classic presentation includes the presence of multifocal to coalescing, firm, white to grey neoplastic nodules in visceral organs, including the liver, spleen, kidneys, gonads, heart, and lungs. In cases of hypervirulent MDV (HV-MDV) strains, the disease is often more acute, with severe hepatosplenomegaly and profound atrophy of the bursa of Fabricius and thymus, hallmarks of the early cytolytic infection that can precede frank tumor formation [1, 19]. Furthermore, diffuse enlargement of the peripheral nerves, particularly the brachial and sciatic plexuses, with a loss of normal striated appearance, is a pathognomonic finding for the classical neural form of MD. The differentiation of these gross lesions from those caused by other avian oncogenic viruses, such as avian leukosis virus (ALV) and reticuloendotheliosis virus (REV), is critical but often insufficient without ancillary testing, especially given the increasing prevalence of co-infections [21, 25, 28].

Histopathological and Immunohistochemical (IHC) Confirmation

To achieve a definitive diagnosis, histopathological examination of affected tissues is essential. The microscopic hallmark of MD is the infiltration of tissues by a pleomorphic population of lymphoid cells, including a mixture of large lymphoblasts, medium-sized lymphocytes, and plasma cells, with a predominance of T-cells. In neoplastic lesions, particularly in visceral lymphomas, the cell population is more monomorphic and consists of neoplastic T-lymphoblasts. Widespread evidence of lymphocyte depletion in the bursa and thymus, accompanied by follicular atrophy, is a key indicator of the early cytolytic phase of infection, which is distinct from the later proliferative and neoplastic stages [19]. Immunohistochemistry (IHC) has become an indispensable tool for confirming the T-cell origin of these neoplasms. Staining with monoclonal antibodies against CD3, a pan-T-cell marker, is the standard technique to differentiate MDV-induced lymphomas from B-cell lymphomas associated with other viruses, such as REV or ALV-J [38]. IHC can also be employed to detect specific MDV antigens, such as the pp38 phosphoprotein or the Meq oncoprotein, within tissue sections, providing direct evidence of viral protein expression at the cellular level [12, 34]. The dual application of hematoxylin and eosin (H&E) staining for morphological assessment and IHC for immunophenotyping and viral antigen detection forms the gold standard for pathological diagnosis, particularly in cases where clinical signs are ambiguous or masked by vaccination.

Molecular Detection: PCR and Real-Time PCR Assays

The advent of molecular diagnostics has revolutionized MDV detection, offering unparalleled sensitivity, specificity, and the ability to differentiate between pathogenic MDV serotype 1 (GaHV-2) and the non-pathogenic vaccine strains of serotype 2 (GaHV-3) and serotype 3 (MeHV-1, or HVT). Polymerase chain reaction (PCR) targeting conserved genes such as glycoprotein B (gB), the Meq oncogene, or the pp38 gene is widely employed for the rapid identification of MDV DNA in clinical samples, including blood, spleen, feather tips, and dust [12, 25, 33]. The use of multiplex real-time PCR (qPCR) is particularly powerful, enabling the simultaneous detection and quantitation of MDV-1, MDV-2, and HVT genomes directly from clinical material. This technique is crucial for monitoring vaccine take, determining viral load in the feather follicle epithelium (the primary site of shedding), and assessing the degree of vaccine virus replication in the host [34, 38]. Quantitative PCR has also been instrumental in demonstrating the synergistic replication of MDV with other viruses, such as REV and ALV-J, where increased viral loads correlate with enhanced pathogenicity and tumor formation [21, 28]. Moreover, molecular typing through sequencing of the Meq gene, which is under strong positive selection and contains polymorphisms associated with virulence, provides critical insights into the pathotype of circulating field strains. Detection of specific amino acid substitutions, such as those in the proline-rich region (e.g., P176A, P217A, P233L) and the presence of L-Meq or S-Meq isoforms, can identify very virulent plus (vv+) strains and track the ongoing evolution of the virus towards higher virulence [5, 12, 24].

Advanced Diagnostic Techniques: Recombinase Polymerase Amplification (RPA) and Serology

While PCR is a laboratory-standard technique, its requirement for thermal cyclers limits its use in field settings. The development of a real-time recombinase polymerase amplification (RPA) assay specifically for MDV-1 addresses this gap. This isothermal amplification method can detect the Meq gene with high sensitivity (detection limit of 100 copies/µL) and specificity, showing no cross-reactivity with other common avian pathogens or vaccine strains. The entire reaction is completed in 20 minutes at a constant temperature of 39°C, making it a highly portable and rapid point-of-care diagnostic tool for resource-limited environments or for on-farm surveillance [33]. Serological assays, including agar gel immunodiffusion (AGID) and enzyme-linked immunosorbent assay (ELISA), remain valuable for screening flocks for exposure to MDV. AGID can detect precipitating antibodies against both pathogenic and vaccine strains, providing evidence of past infection or vaccination. ELISA platforms are more suitable for high-throughput screening and can differentiate between antibody responses to different serotypes. However, serology has limitations, as the presence of maternally derived antibodies in young chicks can confound results, and infected birds may not seroconvert until late in the infection. The detection of viral-specific antibodies is therefore more useful for epidemiological surveillance and monitoring vaccine efficacy rather than for diagnosing acute disease.

Immunological and Exosomal Biomarkers

The study of cellular immune responses has opened new avenues for diagnostic and prognostic assessment. The use of interferon-gamma (IFN-γ) ELISPOT assays to measure T-cell responses against specific MDV antigens, such as pp38 and Meq, has demonstrated a direct correlation between the magnitude of the IFN-γ response and resistance to MD. This is particularly evident in chickens with the resistant MHC B21 haplotype, where higher frequencies of IFN-γ-producing CD8⁺ αβ and γδ T cells are observed following infection or vaccination [15, 35]. Such assays can serve as functional diagnostic tools to assess the immunological status of a flock and the efficacy of a vaccine regimen. More recently, the analysis of serum exosomes has revealed a treasure trove of potential biomarkers. Exosomes from vaccinated, protected birds are enriched with tumor-suppressor microRNAs and full-length viral mRNAs, suggesting a role for these vesicles in systemic immune surveillance. In contrast, exosomes from tumor-bearing birds are enriched with oncogenic viral miRNAs (e.g., MDV-miR-M4) and mRNAs from the viral repeat regions. These distinct exosomal cargoes offer a non-invasive, blood-based method for diagnosing impending tumorigenesis and evaluating the protective state of the host, potentially far earlier than gross clinical signs appear [36]. Additionally, the documented induction of the unfolded protein response (UPR) in a pathotype-specific manner, with vv+ strains causing the most pronounced activation, suggests that monitoring levels of GRP78/BiP or XBP1 splicing in lymphocytes could serve as a molecular correlate of virulence [27].

Differential Diagnosis and the Imperative of Co-Infection Detection

A critical component of any diagnostic approach is the exclusion of other disease entities that can mimic MD. The lymphoproliferative lesions of MD must be distinguished from those caused by REV, ALV-J, and other herpesviruses. This differentiation is not merely academic, as co-infections with MDV and REV [21, 25] or MDV and ALV-J [28] have been shown to synergistically increase viral replication, mortality, and tumor incidence while simultaneously reducing vaccine efficacy. In the case of MDV/REV co-infection, the protective index of even the gold-standard CVI988 vaccine can drop dramatically [21]. Therefore, a comprehensive diagnostic workup must include specific PCR assays for GaHV-1 (ILTV), REV, and ALV-J in conjunction with MDV typing. In summary, the diagnostic approach to MDV infection must be dynamic and layered, incorporating gross and histopathology, targeted molecular detection, quantitative viral load assessment, pathotyping through Meq sequencing, immunological profiling via ELISPOT, and exploration of emerging biomarkers like exosomal cargo. This multi-pronged strategy is essential not only for diagnosing clinical outbreaks but also for understanding the mechanisms of vaccine failure, monitoring the relentless evolution of virulence in the field, and informing the development of next-generation vaccines and control measures.

Vaccination Strategies and Immune Protection Against Marek’s Disease Virus

The control of Marek’s disease (MD) represents one of the most complex and instructive case studies in the annals of veterinary vaccinology. Since the introduction of the first live-attenuated vaccine in the late 1960s, the relationship between Gallid alphaherpesvirus 2 (GaHV-2; MDV) and its host has been fundamentally reshaped. While vaccination has dramatically reduced mortality and tumor incidence on a global scale, it has paradoxically driven the emergence of increasingly virulent pathotypes that now challenge the very foundation of our control strategies [1, 3, 6]. The current armamentarium of vaccines, predominantly serotype 1 (CVI988/Rispens), serotype 2 (SB-1), and serotype 3 (HVT, derived from turkeys [4]), has been applied for decades, yet sterilizing immunity remains an unattained goal. This section provides an exhaustive analysis of the immunological principles underlying vaccine-induced protection, the mechanisms by which MDV strains evade this immunity, and the emerging strategies being developed to meet the challenge of hypervirulent field isolates.

The Co-Evolutionary Arms Race: Vaccine-Driven Virulence and the Limits of Current Protection

The trajectory of MDV virulence over the past century is a stark illustration of how anthropogenic interventions, intensive farming and mass vaccination, can inadvertently accelerate pathogen evolution. Phylogenomic analyses have demonstrated that MDV has been circulating in chickens for at least a millennium, but its transformation from a relatively mild pathogen to a hypervirulent killer coincided with the industrialization of poultry production and the advent of vaccination [2, 6]. Critically, the emergence of highly virulent strains in both North America and Eurasia maps temporally to the widespread adoption of vaccination programs, with time-calibrated phylogenies revealing a mean evolutionary rate of approximately 1.6 × 10⁻⁵ substitutions per site per year, a pace that facilitates rapid adaptation under strong selective pressure [6]. This acceleration is particularly evident in the Meq oncogene, a key virulence determinant and transcription factor, where positive selection has fixed mutations that enhance transactivation activity and pathogenicity. The meq locus is evolving at a rate comparable to RNA viruses, despite being a double-stranded DNA virus, and its divergence coincides with the introduction of live-attenuated vaccines [10]. Notably, insertions (L-Meq) and deletions (S-Meq) within the Meq protein directly impact virulence: recombinant viruses encoding L-Meq induce higher mortality and tumor incidence, while S-Meq paradoxically reduces virulence despite increased transactivation activity, suggesting that complex epistatic interactions govern the net pathogenic outcome [5].

The practical consequence of this evolution is starkly demonstrated by recent analyses of field isolates. Studies from China, a region of intense poultry production, have identified hypervirulent MDV (HV-MDV) strains, SDCW01, HNXZ05, HNSQ05, and HNSQ01, that induce cumulative MD incidences of 90–100% and mortality rates of 60–86.7% in unvaccinated birds, with gross tumor occurrences ranging from 30–63.3% [1]. More alarmingly, the protective indices (PIs) of commercial vaccines against these strains are critically compromised. In head-to-head comparisons, the PIs for CVI988 (monovalent), HVT, CVI988+HVT (bivalent), and the Chinese vaccine strain 814 were only 46.2%, 38.5%, 50%, and 28%, respectively [1]. Birds receiving even the gold-standard CVI988 still developed tumors (cumulative incidence 7.7%), as did HVT-vaccinated birds (11.5%) [1]. These data underscore a fundamental failure: vaccines that once conferred near-complete protection against early pathotypes are now partially or wholly ineffective against contemporary hypervirulent strains. This pattern is not confined to China; very virulent plus (vv+) strains have been molecularly characterized in Colombia, with Meq sequences showing 99% identity to Asian vv+ isolates and carrying hallmark proline-rich region mutations (P176A, P217A, P233L) [12], and in US flocks, where complete genome sequencing of 70 strains over decades has revealed a clear phylogenetic separation by virulence class, with high-virulence isolates persisting on farms despite eradication attempts [9].

Mechanisms of Vaccine-Induced Immunity: Cellular Responses, MHC Restriction, and the Role of Innate Effectors

Vaccine-mediated protection against MDV is predominantly cell-mediated, with humoral immunity playing a secondary role. The live-attenuated vaccines currently in use (e.g., CVI988, HVT, SB-1) replicate in the host without causing overt disease, establishing a persistent infection that primes both innate and adaptive arms of the immune system. However, the precise correlates of protection remain incompletely defined, and the effectiveness of these responses is highly dependent on host genetics, particularly the major histocompatibility complex (MHC) haplotype.

T-cell-mediated immunity is the cornerstone of MDV control. Infection with virulent MDV, as well as vaccination, induces robust T-cell responses, with the magnitude and quality of these responses directly correlating with resistance. Chickens of the B21 MHC haplotype (MD-resistant line N) exhibit significantly higher frequencies of interferon-gamma (IFN-γ)-producing T cells specific for viral antigens pp38 and Meq compared to B19 haplotype chickens (MD-susceptible line P2a) [15]. Crucially, vaccination fails to induce or boost Meq-specific effector T cells in susceptible birds, while it amplifies both pp38- and Meq-specific responses in resistant lines [15]. This differential response is underpinned by the unique peptide-binding properties of chicken class II molecules. Immunopeptidomic analysis of the dominantly expressed BL2*02 molecule (from the resistant B2 haplotype) revealed that it presents viral peptides from only four MDV genes, with a core binding motif of 10 amino acids, an unprecedented length in class II molecules, resulting from a single amino acid substitution that creates a crinkle in the peptide backbone [16]. This extreme restriction of the immunopeptidome provides a mechanistic explanation for how a limited number of MHC haplotypes can confer decisive resistance or susceptibility to a complex virus with over 100 genes, and it suggests that vaccine efficacy may be optimized by matching antigen formulations to common MHC haplotypes in target flocks.

The role of unconventional T cells, particularly γδ T cells, has garnered increasing attention. MDV vaccination induces IFN-γ⁺CD8α⁺ γδ T cells and TGF-β⁺ γδ T cells in the lungs, and these cells from vaccinated/challenged chickens exhibit maximum cytotoxic activity upon ex vivo stimulation [35]. Infected animals also show a significant increase in splenic γδ T cells by 10–21 days post-infection, nearly all of which become CD8⁺, and these cells upregulate IFN-γ early in infection before shifting to IL-10 expression during later phases [37]. This temporal shift suggests that γδ T cells may play a dual role, initially contributing to antiviral control and later potentially modulating inflammation and immunopathology.

Natural killer (NK) cells, key effectors of the innate immune response, are also directly targeted and modulated by MDV. Primary chicken NK cells are efficiently infected by both the very virulent RB-1B strain and the CVI988 vaccine virus [39]. Infection enhances NK cell degranulation and IFN-γ production, and the Meq oncogene contributes to this activation, as meq knockout viruses show reduced NK cell activation [39]. This finding is paradoxical: while NK cells are critical for early control of viral infection, their activation by MDV may also contribute to the cytokine storm and immunopathology associated with acute infection. Nevertheless, host resistance to MDV is associated with differences in NK cell responses, reinforcing their importance in the protective immune landscape.

Beyond cellular effectors, a novel mechanism of systemic immunity has been proposed based on the characterization of serum exosomes. Exosomes from CVI988-vaccinated and protected chickens (VEX) are enriched in tumor suppressor microRNAs and contain mRNAs mapping to the entire MDV genome, whereas exosomes from tumor-bearing birds (TEX) are enriched in oncomiRs and contain only mRNAs from the viral repeat regions [36]. This suggests that vaccine-induced exosomes may serve as systemic vectors, transferring viral mRNAs to antigen-presenting cells and thereby maintaining long-term immune surveillance [36]. If confirmed, this exosome-based mechanism could represent a critical, and previously unrecognized, component of vaccine-mediated protection.

The Achilles' Heel: Failure to Prevent Replication, Shedding, and Co-Infection

Despite their success in preventing clinical disease and tumors, current MDV vaccines do not provide sterile immunity. Vaccinated birds can still be infected with field strains, and these strains can replicate, be shed into the environment, and circulate within flocks [3, 7, 34]. This incomplete protection is the engine driving virulence evolution: the vaccine creates a selective environment where only strains that can overcome the vaccine-induced immune response are able to transmit. Mathematical modeling of MDV transmission dynamics on commercial broiler farms reveals that virus dynamics are influenced by between-flock variation in host susceptibility, shedding rate, and the efficacy of farm cleanout procedures, and that virus is reintroduced to farms approximately once per month [29]. These models predict that changes in farming practices, such as improved biosecurity or reduced stocking density, can significantly impact transmission and, consequently, the selection pressure for virulence.

The immune evasion mechanisms employed by MDV directly undermine vaccine efficacy. The virus encodes multiple proteins that antagonize the host interferon response, a critical component of the antiviral state. The VP23 tegument protein inhibits the cGAS-STING DNA-sensing pathway by binding to IRF7 and blocking its interaction with TBK1, thereby suppressing IRF7 phosphorylation and nuclear translocation [18]. Similarly, the RLORF4 protein binds the Rel homology domains of NF-κB subunits p65 and p50, preventing their nuclear translocation and inhibiting IFN-β production [26]. These viral countermeasures not only facilitate wild-type virus replication but also blunt the response to vaccine strains, reducing the overall magnitude of the innate immune response and allowing breakthrough infection.

Furthermore, MDV-induced immunosuppression, characterized by atrophy of the thymus and bursa of Fabricius, compromises the host's ability to mount effective immune responses. Lytic infection in these primary lymphoid organs induces massive apoptosis, with distinct mechanisms operating in each organ: in the thymus, most infected cells are apoptotic, while in the bursa, most apoptotic cells are uninfected bystander B cells [19]. This results in severe B-lymphopenia during the first two weeks of infection, further impairing the adaptive immune response [19]. Vaccination itself, particularly with live-attenuated strains, can also cause some degree of lymphoid atrophy, although this is generally less severe than that induced by virulent viruses. The double deletion mutant ΔMeqΔvIL8 has been shown to significantly reduce lymphoid organ atrophy compared to meq-null viruses while maintaining protective efficacy comparable to CVI988 [8], suggesting that future vaccine designs must weigh safety (minimal immunosuppression) against immunogenicity.

Co-infections further complicate the vaccination landscape. In the field, MDV frequently coexists with other immunosuppressive and oncogenic viruses, including reticuloendotheliosis virus (REV) and avian leukosis virus subgroup J (ALV-J). Co-infection of chickens with MDV and REV significantly increases mortality (from 76.7% to 96.7%) and tumor rates (from 53.3% to 80.0%), and reduces the protective index of CVI988 from 80.0 to 47.7 [21]. Similarly, superinfection with MDV and ALV-J synergistically enhances replication of both viruses and promotes expression of IL-10, IL-6, and TGF-β, leading to more severe cytopathy and higher mortality [28]. These findings have profound implications for vaccine strategy in regions where multiple oncogenic viruses are enzootic, as the efficacy of MD vaccines may be significantly lower than laboratory challenge studies suggest.

Next-Generation Vaccination Strategies: Gene Editing, Rationally Attenuated Strains, and Metabolic Interference

Given the failure of conventional vaccines to prevent hypervirulent strain emergence, the field is moving toward novel approaches that either (a) provide broader and more durable immunity, (b) block virus replication at a fundamental level, or (c) are inherently less susceptible to antigenic drift.

Rationally attenuated recombinant vaccines offer the potential to combine high immunogenicity with defined safety profiles. The meq gene, the primary oncogene, is an obvious target. Deletion of meq from a vv+ MDV backbone (686BAC-ΔMeq) attenuates the virus and provides protection against challenge, but it still induces significant lymphoid organ atrophy [8]. To address this, a double deletion mutant lacking both meq and the chemokine homolog vIL-8 (686BAC-ΔMeqΔvIL8) was constructed. This mutant replicates equivalently to the parental vv+ strain in vitro but does not cause lymphoid organ atrophy in vivo, while conferring protection comparable to CVI988 against vv+ challenge [8]. The vIL-8 deletion is critical because it abrogates the chemoattraction of B cells, the initial target of MDV lytic replication, thereby reducing the early amplification of the virus and the associated immunopathology. This strategy exemplifies how mechanistic understanding of viral pathogenesis can guide the design of safer and more effective vaccines.

The application of CRISPR/Cas9-based gene editing has opened transformative possibilities, both for generating novel vaccine candidates and for direct antiviral therapy. The CRISPR/Cas9 system can be used to efficiently mutate MDV-encoded microRNAs (e.g., the Meq- or mid-clustered miRNAs) in the context of the viral genome, enabling the construction of rationally attenuated viruses with precisely defined deletions [20]. More spectacularly, guide RNAs targeting essential MDV genes can block virus replication in cell culture, and combining two or more guides completely abrogates replication without the emergence of escape mutants, even upon serial passaging [32]. While this proof-of-concept has yet to be translated into an in vivo delivery system, it raises the prospect of CRISPR-based immunity that could be conferred to vaccinated birds, preventing both disease and virus transmission. The challenge remains to develop efficient, affordable delivery systems for in ovo or post-hatch administration to billions of chickens annually.

The gut microbiota represents an unexpected but promising axis for intervention. Depletion of the gut microbiota in chickens increases the severity of MD following infection, with elevated transcription of IFN-α, IFN-β, and IFN-γ in the bursa of Fabricius at 4 days post-infection [40]. This suggests that the commensal microbiota normally contributes to immune regulation and protection against MDV, possibly by priming the host immune system or by competing with the virus for resources. Modulating the microbiota through probiotics or prebiotics could therefore serve as an adjunct to vaccination, enhancing baseline immunity and potentially reducing the effective dose of vaccine required.

Finally, metabolic targeting is emerging as a novel antiviral strategy. MDV hijacks host cellular metabolism, upregulating glycolysis and glutaminolysis to provide energy and biosynthetic precursors for its replication [17]. Inhibition of glutaminolysis or glycolysis significantly impairs MDV replication in vitro, while fatty acid β-oxidation is dispensable [17]. Pharmacological agents that target these metabolic pathways, such as glutamine analogs or glycolytic inhibitors, could be developed as feed additives or therapeutic interventions to suppress virus replication in vaccinated flocks, thereby reducing shedding and the

Emergence of Hypervirulent Marek’s Disease Virus Variants and Vaccine Breakthrough

The evolutionary trajectory of Marek’s disease virus (MDV) represents one of the most compelling and economically consequential case studies in pathogen virulence escalation within modern agriculture. Over the past six decades, the virus has undergone a pronounced and well-documented shift from a relatively benign pathogen capable of causing mild neurological signs to a hypervirulent oncogenic agent that can induce rapid-onset T-cell lymphomas and death in over 90% of unvaccinated birds [1, 2]. This transformation is inextricably linked to the intensification of poultry production systems and, paradoxically, to the very vaccination strategies employed to control the disease. The emergence of hypervirulent MDV variants that can significantly overcome the immune protection conferred by the current generation of commercial vaccines has become one of the most urgent challenges facing the global poultry industry, with annual economic losses exceeding US$1 billion worldwide due to mortality, condemnations, and control measures [1, 2].

Historical Context and the Stepwise Escalation of Virulence

The evolutionary history of MDV virulence is not a gradual, linear progression but rather a punctuated escalation driven by selective pressures imposed by successive generations of vaccines. Through the application of ancient DNA sequencing techniques on archaeological chicken remains spanning at least 1,000 years, researchers have convincingly demonstrated that ancestral MDV strains were likely incapable of driving the robust tumor formation observed in modern isolates [2]. Functional paleogenomic testing of the ancestral meq oncogene, a critical transcription factor and the primary driver of MDV oncogenicity, revealed a markedly reduced capacity for cellular transformation compared to its contemporary counterparts [2]. The major shift toward virulence appears to have coincided with the industrialization of poultry farming in the 1950s and, critically, with the introduction and widespread adoption of live-attenuated vaccines in the 1970s [2, 6].

Phylogenomic analyses have revealed geographically independent paths to virulence, with reconstructions supporting the emergence of virulent viruses separately in North America and Eurasia, each following the implementation of comprehensive vaccination programs on those continents [6]. This temporal correlation strongly suggests that vaccination, while effective at preventing clinical disease and tumor formation, has created an ecological niche that favors the selection and transmission of increasingly virulent strains. The current landscape is characterized by the existence of pathotypes ranging from mild (mMDV) to virulent (vMDV), very virulent (vvMDV), and the most recent and concerning category: very virulent plus (vv+MDV) strains [3, 9]. This continuum of virulence has been documented through systematic characterization of field isolates over decades, with each increase in pathotype corresponding to a diminished efficacy of the preceding vaccine generation.

Molecular Determinants of Hypervirulence: The Central Role of the Meq Oncogene

At the molecular epicenter of MDV hypervirulence lies the meq gene, an MDV-encoded basic leucine zipper (bZIP) transcription factor that is a functional homologue of the cellular Jun/Fos family and serves as the primary oncoprotein driving lymphomagenesis [5, 23]. The meq gene has undergone intense positive selection pressure, evolving at a rate comparable to that of RNA viruses, a striking finding for a double-stranded DNA virus with a typically more stable genome [10]. This accelerated evolution is particularly evident in the C-terminal transactivation domain of the Meq protein, where specific amino acid polymorphisms, insertions, and deletions have become hallmarks of hypervirulent strains.

The detailed characterization of Meq variants from field isolates has identified several critical structural alterations that correlate with enhanced virulence. Insertions in the Meq protein, designated as L-Meq isoforms, significantly enhance the transactivation potential of the oncoprotein, leading to increased mortality and tumor incidence in experimentally infected chickens [5]. Conversely, certain deletions, while paradoxically increasing transactivation activity in reporter assays, resulted in attenuated pathogenicity in vivo, indicating that the relationship between Meq function and virulence is complex and likely involves additional domains of the protein beyond its transcriptional activation capacity [5]. The amino acid substitutions P176A, P217A, and P233L within the proline-rich region of Meq have been consistently associated with vv+MDV pathotypes, and these markers have been used to characterize emerging hypervirulent strains in geographically disparate regions, including Colombia, China, and the United States [9, 12].

Beyond its direct role in tumorigenesis, the Meq protein orchestrates a multifaceted strategy for immune evasion and cellular reprogramming. Meq directly interacts with the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K), activating the PI3K/Akt signaling pathway to delay apoptosis in infected cells and thereby promote efficient viral replication [23]. This activation of a canonical survival pathway is a hallmark of many oncogenic viruses and underscores how Meq subverts fundamental host cell biology to favor persistent infection and transformation. Furthermore, the meq transcriptional unit is a hotspot for the generation of viral circular RNAs (circRNAs), a recently rediscovered class of noncoding RNAs that are expressed during viral replication, latency, and reactivation [14]. These circRNAs, produced from both the meq locus and the latency-associated transcripts (LATs), add a previously unappreciated layer of regulatory complexity to MDV pathogenesis and may contribute to the enhanced virulence of modern field strains through post-transcriptional regulation of viral and cellular gene expression [14].

Immune Evasion and Antagonism of Host Defenses

The capacity of hypervirulent MDV variants to overcome vaccine-induced immunity is fundamentally rooted in a sophisticated arsenal of immune evasion mechanisms that have been refined through decades of co-evolution with vaccinated hosts. The virus encodes multiple proteins that actively subvert the host interferon (IFN) response, which is a critical first line of antiviral defense. The VP23 protein, a component of the viral tegument, has been identified as a potent inhibitor of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) DNA-sensing pathway [18]. VP23 specifically targets interferon regulatory factor 7 (IRF7), blocking its interaction with TANK-binding kinase 1 (TBK1), thereby preventing IRF7 phosphorylation, nuclear translocation, and subsequent IFN-β induction. This targeted inhibition allows hypervirulent strains to replicate to higher titers in the face of an otherwise effective innate immune response [18].

Similarly, the RLORF4 protein, which has been directly linked to MDV attenuation during serial in vitro passage, functions as an inhibitor of the DNA-sensing pathway by antagonizing NF-κB activation. RLORF4 binds directly to the Rel homology domains of the NF-κB subunits p65 and p50, preventing their nuclear translocation and thereby blocking the production of IFN-β and pro-inflammatory cytokines [26]. Deletion of RLORF4 from the MDV genome results in enhanced IFN-β and interleukin-6 production, reduced viral titers, and increased host cellular immunity, confirming the critical role of this protein in suppressing the antiviral state [26]. The convergence of multiple, non-redundant viral antagonists targeting the same central innate immune pathways, cGAS-STING, IRF7, and NF-κB, underscores the extreme selective pressure that the host IFN system exerts on MDV and explains why hypervirulent strains are particularly adept at establishing infection even in vaccinated birds.

Beyond innate immune antagonism, hypervirulent MDV variants have also evolved strategies to manipulate adaptive immune responses, particularly T-cell immunity, which is essential for vaccine-mediated protection. The major histocompatibility complex (MHC) haplotype of the host is a well-established determinant of susceptibility to MD, with the B21 haplotype conferring resistance and the B19 haplotype conferring susceptibility [15, 16]. Remarkably, immunopeptidomic analyses have revealed that the vast majority of viral peptide epitopes presented by chicken MHC class II molecules derive from only four viral genes, despite MDV encoding over 100 proteins [16]. This highly restricted presentation of viral antigens severely limits the breadth of the T-cell response and may create vulnerabilities that hypervirulent strains can exploit through mutations in these immunodominant epitopes. Furthermore, vaccination fails to induce or boost Meq-specific effector T-cell responses in genetically susceptible chickens, while it effectively boosts both pp38- and Meq-specific responses in resistant lines [15]. This differential responsiveness provides a mechanistic basis for the observed variation in vaccine efficacy across different genetic backgrounds and suggests that hypervirulent strains may have evolved to specifically evade recognition by T cells restricted to common susceptible MHC haplotypes.

Epidemiological Evidence of Vaccine Breakthrough

The theoretical concerns regarding hypervirulent MDV variants have been substantiated by compelling empirical evidence from multiple continents, most notably from China where systematic surveillance has documented the emergence of strains capable of dramatically overcoming the protection conferred by commercial vaccines. In a landmark study published in 2023, researchers isolated seven MDV strains from tumor-bearing chickens in vaccinated flocks and subjected them to rigorous pathogenicity testing [1]. Four of these isolates, designated SDCW01, HNXZ05, HNSQ05, and HNSQ01, were classified as hypervirulent MDV (HV-MDV) strains. In experimental infections, these isolates produced cumulative MD incidences of 100%, 93.3%, 90%, and 100%, with corresponding mortalities of 83.3%, 73.3%, 60%, and 86.7% [1]. The gross occurrence of tumors ranged from 30% to 63.3%, indicating that these strains retained potent oncogenic capacity even in the face of prior vaccination.

The most alarming finding from this study was the evaluation of four commercially available MD vaccines, CVI988 (Rispens), HVT, CVI988+HVT (bivalent), and the Chinese vaccine strain 814, against the SDCW01 hypervirulent isolate. Over 67 days post-challenge, the protection indices (PIs) for these vaccines were only 46.2%, 38.5%, 50%, and 28%, respectively [1]. These values are dramatically lower than the PIs typically expected for these vaccines against standard challenge strains, which routinely exceed 80-90%. Critically, birds vaccinated with monovalent CVI988 or HVT still developed tumors, with cumulative incidences of 7.7% and 11.5%, respectively [1]. This represents a clear and unequivocal demonstration that contemporary hypervirulent MDV field strains can breach the immune barrier provided by the current gold-standard vaccines, a phenomenon that has profound implications for the sustainability of MD control programs worldwide.

The emergence of vaccine breakthrough is not a phenomenon confined to China. In Colombia, molecular characterization of an MDV isolate from a commercial layer farm exhibiting clinical signs consistent with MD revealed a vv+ pathotype based on Meq gene sequence analysis, clustering phylogenetically with Asian hypervirulent strains [12]. These findings indicate that hypervirulent variants are becoming globally distributed, likely facilitated by international trade in poultry and poultry products. The persistence of highly virulent isolates on farms despite eradication attempts has also been documented in the United States, where whole-genome sequencing of 70 MDV strains with known virulence revealed that high-virulence isolates from the same farms persisted over years [9]. This suggests that once hypervirulent strains become established in a production system, they are remarkably difficult to eliminate, even with stringent biosecurity and depopulation protocols.

Coinfections and the Exacerbation of Vaccine Failure

The challenge of controlling hypervirulent MDV is further complicated by the high prevalence of coinfections with other avian oncogenic and immunosuppressive viruses. Field surveys have consistently demonstrated that MDV frequently circulates in concert with reticuloendotheliosis virus (REV) and avian leukosis virus subgroup J (ALV-J), and these coinfections have been shown to synergistically increase disease severity and reduce vaccine efficacy [21, 25, 28]. In experimental coinfection studies using Chinese field strains of MDV and REV, mortality rates increased by 20% (from 76.7% to 96.7%) and tumor rates increased by 26.7% (from 53.3% to 80.0%) compared to MDV challenge alone [21]. The protective index of the CVI988 vaccine decreased by 33.3 points (from 80.0 to 46.7) when birds were co-challenged, representing a catastrophic loss of vaccine efficacy [21]. Similar synergistic effects have been observed with ALV-J superinfection, where dual infection resulted in increased viral replication at both the RNA and protein levels for both viruses, enhanced expression of immunosuppressive cytokines such as IL-10 and TGF-β, and significantly higher mortality and tumor formation rates compared to single infections [28]. The mechanisms underlying this synergism likely involve the immunosuppressive properties of each virus, which collectively create a permissive environment for hypervirulent MDV replication and dissemination, even in the presence of vaccine-induced immunity.

Implications for Future Control Strategies

The convergence of evidence from molecular pathogenesis, phylogenetic evolution, and epidemiological surveillance paints a stark picture: the emergence of hypervirulent MDV variants that can overcome vaccine protection is not a hypothetical future scenario but a present and escalating reality. The World Organisation for Animal Health (WOAH) recognizes MD as a disease of major economic significance, and the Food and Agriculture Organization (FAO) has highlighted the threat posed by evolving poultry pathogens to global food security. The current situation mirrors the pattern observed with each previous vaccine generation: the widespread use of a vaccine selects for field strains with increased virulence that eventually render that vaccine obsolete. The meq-null and vIL-8 deletion mutant vaccines currently under development represent a promising next generation of intervention [8], but history cautions that these too may eventually be overcome. The rapid evolutionary rate of the meq gene, comparable to RNA viruses [10], and the multiplicity of genotypic pathways through which virulence can be achieved [9] suggest that MDV will continue to adapt. The integration of CRISPR/Cas9-based approaches to directly block viral replication [32] and the development of novel vaccines targeting the invariant immune evasion proteins [18, 26] may offer alternative avenues, but the fundamental challenge remains: as long as MDV is permitted to circulate in vaccinated flocks, the evolutionary arms race will continue.

Evolutionary Dynamics and Host-Pathogen Coevolution of Marek's Disease Virus

The evolutionary trajectory of Marek’s disease virus (MDV) represents one of the most compelling and well-documented examples of pathogen virulence escalation in the modern era, a process profoundly shaped by anthropogenic interventions in poultry management and disease control. As the World Organisation for Animal Health (WOAH) recognizes, MDV imposes a staggering economic burden on the global poultry industry, with annual losses exceeding US$1 billion, a figure that reflects both direct mortality and the costs of continuous vaccine development and administration [2]. Understanding the evolutionary dynamics and host-pathogen coevolution of MDV is not merely an academic exercise; it is a critical necessity for anticipating future threats and designing sustainable control strategies. The virus has demonstrated a remarkable capacity for rapid adaptation, circumventing the protective barriers erected by successive generations of vaccines and fundamentally altering the host-pathogen relationship over the past century.

The Paleovirological Record and the Acceleration of Virulence

For decades, the origins of MDV virulence were shrouded in mystery, with the pathogen’s modern, highly oncogenic phenotype being the only frame of reference. The application of ancient DNA sequencing, however, has revolutionized this understanding, revealing a deep evolutionary history that spans at least a millennium. By sequencing MDV genomes from archaeological chicken remains, researchers have demonstrated that ancient strains were basal to all modern lineages, and critically, that they were likely incapable of driving tumor formation [2]. The key molecular distinction centers on the Meq oncogene; functional testing of the ancient Meq protein showed a drastically reduced capacity for driving the cellular proliferation and transformation that characterizes modern MDV [2]. This finding establishes that the hypervirulent phenotype is not an ancestral trait but a relatively recent evolutionary acquisition.

The shift from a benign or mildly pathogenic virus to one that can kill over 90% of unvaccinated birds correlates strongly with the intensification of poultry farming in the mid-20th century, particularly after the 1950s [2, 6]. The advent of large, dense, and genetically uniform flocks created an ecological landscape ripe for pathogen transmission and selection for increased virulence. However, the most profound accelerant was the widespread introduction of live-attenuated vaccines in the 1970s. Phylogenomic analyses have provided robust evidence that the emergence of highly virulent MDV strains occurred independently in North America and Eurasia, and crucially, that this emergence coincided temporally with the implementation of comprehensive vaccination programs on both continents [6]. This suggests that vaccination, while effective at preventing clinical disease and economic losses in the short term, created a permissive environment where higher virulence could evolve.

Genomic Signatures of Positive Selection: The Meq Oncogene as a Molecular Chronometer

The molecular basis for this virulence escalation is polygenic, but no gene has drawn more attention than meq (Marek’s EcoRI-Q), the primary oncogene of MDV. The meq gene is evolving at an astonishing rate for a double-stranded DNA virus, with its evolutionary rate estimated to be comparable to that of RNA viruses, a phenomenon driven by intense positive selection [10]. This rapid evolution is not random; it is highly structured and linked to specific functional domains. Most of the polymorphisms observed in the meq gene have arisen under positive selection, and the timing of divergence at this locus aligns precisely with the period of industrial intensification and vaccine use [10].

The functional consequences of these mutations are becoming increasingly clear. Insertions and deletions within the Meq protein, such as the L-Meq (insertion) and S-Meq (deletion) isoforms, have distinct impacts on viral pathogenicity. The L-Meq insertion enhances the transactivation potential of the protein and, when introduced into a recombinant virus, induces the highest mortality and tumor incidence [5]. Conversely, the S-Meq deletion, while also enhancing transactivation activity in reporter assays, paradoxically results in reduced pathogenicity in vivo, underscoring the complexity of Meq's function beyond simple transcriptional activation [5]. The Meq protein is a master regulator, interacting directly with the p85 regulatory subunit of PI3K to activate the PI3K/Akt signaling pathway, thereby promoting cell survival and viral replication by delaying apoptosis in infected host cells [23]. This interaction is a direct mechanism linking a key virulence-associated protein to a central host survival pathway, illustrating the molecular arms race at the cellular level.

The selective pressures exerted by vaccines are not uniform across the genome. While meq is a primary target, other genes also bear the hallmarks of selection. Whole-genome sequencing of 70 MDV strains with known virulence from the United States identified multiple genetic variants associated with virulence, confirming that the trait is complex and multigenic [9]. This is further corroborated by studies showing that Chinese field isolates, which have broken through vaccine protection, possess specific signature mutations in meq, pp38, and vIL-8 that have become fixed in the circulating population [1, 24]. The identification of hypervirulent strains (HV-MDV) in China that can significantly overcome the protection conferred by the current gold-standard CVI988 vaccine, as well as bivalent HVT+CVI988 combinations, demonstrates that the coevolutionary trajectory continues unabated, with field strains outpacing vaccine development [1].

Beyond Meq: Multigenic Determinants of Virulence and Immune Evasion

The evolutionary narrative of MDV is not confined to the meq gene. A suite of other viral genes is under active selection, each contributing to the virus's ability to replicate, spread, evade host immunity, and cause pathology. The RLORF4 gene, for example, is a potent inhibitor of the host's innate immune response. This protein functions by binding to the Rel homology domains of the NF-κB subunits p65 and p50, thereby blocking their nuclear translocation and inhibiting the production of type I interferons (IFN-β) [26]. Deletion of RLORF4 from the MDV genome leads to increased IFN-β production and reduced viral titers in vivo, confirming its role as a key virulence factor that dampens the host's first line of defense [26]. Similarly, the VP23 protein inhibits the cGAS-STING DNA-sensing pathway by interacting with IRF7 and blocking its interaction with TBK1, thereby suppressing IRF7 activation and subsequent IFN-β production [18]. These immune evasion mechanisms are directly selected for, as they allow the virus to replicate to higher titers in the face of a host immune response.

The emergence of hypervirulence also involves novel molecular mechanisms, such as the expression of circular RNAs (circRNAs). Deep sequencing and genome-wide analyses have revealed that MDV produces a large variety of circRNAs, with hot spots of expression mapping to the transcriptional units of the meq oncogene and the latency-associated transcripts (LATs) [14]. These circRNAs are expressed during key stages of the viral lifecycle, including latency and reactivation, and are found abundantly in lymphoma-derived samples [14]. The fact that these non-coding RNAs originate from the most critical virulence genes adds another layer of complexity to the virus's regulatory network, potentially offering new targets for intervention.

Furthermore, the evolution of transmission mechanisms is itself under selection. The tegument protein pUL47 has been identified as an essential factor for horizontal bird-to-bird transmission [31]. Intriguingly, pUL47 is not required for cell-to-cell spread in vitro or for virulence in vivo, but it is absolutely necessary for the virus to be shed from the host and infect naive contact animals [31]. This function is mediated through pUL47's role in enhancing the splicing and expression of glycoprotein gC (UL44), which is also critical for transmission [31]. The selection for efficient transmission is a powerful evolutionary force, and the conservation of such mechanisms highlights that virulence and transmissibility are inextricably linked in the MDV system.

The Coevolutionary Crucible: Host Genetics and Vaccine-Driven Selection

The coevolutionary arms race is not one-sided; the host, Gallus gallus domesticus, exerts its own selective pressures. Genetic resistance to MDV is a complex polygenic trait, but the major histocompatibility complex (MHC) plays an exceptionally dominant role, more so than in most other viral systems [16, 30]. The B21 MHC haplotype is associated with resistance, while the B19 haplotype confers susceptibility [15]. The molecular basis for this differential resistance has been illuminated by immunopeptidomics, which revealed that the dominant class II molecule of the resistant B2 haplotype (BL2*02) presents a surprisingly limited repertoire of viral peptides, derived from only four MDV genes [16]. This constrains the CD4+ T cell response, suggesting that the quality, rather than the quantity, of the antigen presentation is crucial for protection. Resistant chickens mount higher frequencies of IFN-γ-producing T cells specific for pp38 and Meq antigens following vaccination and challenge, whereas susceptible chickens fail to generate such MEQ-specific effector T cells after vaccination [15].

This genetic landscape becomes the substrate upon which the virus evolves. The widespread use of vaccines that do not provide sterilizing immunity has created a powerful selective force. Vaccinated birds survive but can still be infected, shed virulent virus, and act as reservoirs [29]. The vaccines essentially reduce the fitness cost of carrying a highly virulent virus, a virus that would otherwise kill its host before transmission, thereby allowing these hyperpathogenic strains to circulate and become dominant [10]. This is the crux of the "vaccine-driven evolution" hypothesis. Mathematical models of MDV transmission have confirmed that farm-level factors, such as host susceptibility, shedding rates, and cleaning efficiency, dictate the virus's ecological and evolutionary dynamics [29]. These models provide a framework for predicting how changes in management practices could alter the trajectory of virulence escalation.

Ecological Complexity and Emergent Pathogenicity: Coinfections and Transmission Dynamics

The evolutionary trajectory of MDV is further complicated by its interactions with other pathogens. Co-infection with reticuloendotheliosis virus (REV) is a common occurrence in the field, and experimental studies have demonstrated a clear synergistic effect. Co-challenged chickens exhibit significantly higher mortality and tumor rates, and the protective index of vaccines like CVI988 drops dramatically [21]. This is not merely an additive effect; the presence of REV appears to alter the host environment, allowing for increased expression of MDV pathogenicity-related genes like meq, pp38, and vIL-8 [21]. Similarly, superinfection with avian leukosis virus subgroup J (ALV-J) synergistically enhances the replication of both viruses at the RNA and protein level, leading to more severe cytopathy, higher mortality, and increased tumor metastasis [28]. These findings underscore that MDV evolution occurs within a complex microbial community, where co-infections can exert novel selective pressures and accelerate the emergence of pathogenic variants.

Finally, the virus's interaction with anatomical structures like the skin and feather follicle epithelium is a critical arena for evolution. The feather follicle is the only site where cell-free infectious virions are produced, making it the sole source of environmental contamination and airborne transmission [34]. The virus has evolved to exploit this niche, and the efficiency of this process, specifically the production and stability of cell-free virus in feather dander, is a trait under strong selection. The recent isolation of hypervirulent strains that produce high levels of virus and cause severe atrophy of the immune organs [1] suggests that selection for efficient transmission and immune evasion are tightly coupled. The very factors that make a strain "successful" in a vaccinated flock, high replication rate, immune suppression, and efficient shedding, are the same factors that drive its virulence to ever-increasing heights, perpetuating a coevolutionary cycle that has proven remarkably difficult to break.

References

[1] Liu J, Teng M, Zheng L, Zhu F, Ma S, Li L, et al.. Emerging Hypervirulent Marek’s Disease Virus Variants Significantly Overcome Protection Conferred by Commercial Vaccines. Viruses. 2023. DOI: https://doi.org/10.3390/v15071434

[2] Fiddaman SR, Dimopoulos E, Lebrasseur O, Plessis Ld, Vrancken B, Charlton S, et al.. Ancient chicken remains reveal the origins of virulence in Marek’s disease virus. Science. 2023. DOI: https://doi.org/10.1126/science.adg2238

[3] Bertzbach LD, Conradie AM, You Y, Kaufer B. Latest Insights into Marek’s Disease Virus Pathogenesis and Tumorigenesis. Cancers. 2020. DOI: https://doi.org/10.3390/cancers12030647

[4] Witter RL, Nazerian K, Purchase H, Burgoyne G. Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek's disease virus.. American Journal of Veterinary Research. 1970. DOI: https://doi.org/10.2460/ajvr.1970.31.03.525

[5] Sato J, Murata S, Yang Z, Kaufer B, Fujisawa S, Seo H, et al.. Effect of Insertion and Deletion in the Meq Protein Encoded by Highly Oncogenic Marek’s Disease Virus on Transactivation Activity and Virulence. Viruses. 2022. DOI: https://doi.org/10.3390/v14020382

[6] Trimpert J, Groenke N, Jenckel M, He S, Kunec D, Szpara ML, et al.. A phylogenomic analysis of Marek's disease virus reveals independent paths to virulence in Eurasia and North America. Evolutionary Applications. 2017. DOI: https://doi.org/10.1111/eva.12515

[7] Yang Y, Dong M, Hao X, Qin A, Shang S. Revisiting cellular immune response to oncogenic Marek’s disease virus: the rising of avian T-cell immunity. Cellular and Molecular Life Sciences. 2020. DOI: https://doi.org/10.1007/s00018-020-03477-z

[8] Liao Y, Reddy S, Khan OA, Sun A, Lupiani B. A Novel Effective and Safe Vaccine for Prevention of Marek’s Disease Caused by Infection with a Very Virulent Plus (vv+) Marek’s Disease Virus. Vaccines. 2021. DOI: https://doi.org/10.3390/vaccines9020159

[9] Dunn J, Pyrkosz AB, Steep A, Cheng HH. Identification of Marek's disease virus genes associated with virulence of US strains.. Journal of General Virology. 2019. DOI: https://doi.org/10.1099/jgv.0.001288

[10] Padhi A, Parcells M. Positive Selection Drives Rapid Evolution of the meq Oncogene of Marek’s Disease Virus. PLoS ONE. 2016. DOI: https://doi.org/10.1371/journal.pone.0162180

[11] Vychodil T, Conradie AM, Trimpert J, Aswad A, Bertzbach LD, Kaufer B. Marek’s Disease Virus Requires Both Copies of the Inverted Repeat Regions for Efficient In Vivo Replication and Pathogenesis. Journal of Virology. 2020. DOI: https://doi.org/10.1128/JVI.01256-20

[12] López-Osorio S, Piedrahita D, Espinal‐Restrepo MA, Ramírez-Nieto G, Nair V, Williams SM, et al.. Molecular characterization of Marek's disease virus in a poultry layer farm from Colombia. Poultry Science. 2017. DOI: https://doi.org/10.3382/ps/pew464

[13] Kheimar AM, Previdelli R, Wight D, Kaufer B. Telomeres and Telomerase: Role in Marek’s Disease Virus Pathogenesis, Integration and Tumorigenesis. Viruses. 2017. DOI: https://doi.org/10.3390/v9070173

[14] Chasseur AS, Trozzi G, Istasse C, Petit A, Rasschaert P, Denesvre C, et al.. Marek’s Disease Virus Virulence Genes Encode Circular RNAs. Journal of Virology. 2022. DOI: https://doi.org/10.1128/jvi.00321-22

[15] Boodhoo N, Behboudi S. Differential Virus-Specific IFN-Gamma Producing T Cell Responses to Marek’s Disease Virus in Chickens With B19 and B21 MHC Haplotypes. Frontiers in Immunology. 2022. DOI: https://doi.org/10.3389/fimmu.2021.784359

[16] Halabi S, Ghosh M, Stevanović S, Rammensee H, Bertzbach LD, Kaufer B, et al.. The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek’s disease virus peptides by using an unprecedented binding motif. PLoS Biology. 2021. DOI: https://doi.org/10.1371/journal.pbio.3001057

[17] Boodhoo N, Kamble N, Sharif S, Behboudi S. Glutaminolysis and Glycolysis Are Essential for Optimal Replication of Marek’s Disease Virus. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.01680-19

[18] Gao L, Li K, Zhang Y, Liu Y, Liu C, Zhang Y, et al.. Inhibition of DNA-Sensing Pathway by Marek's Disease Virus VP23 Protein through Suppression of Interferon Regulatory Factor 7 Activation. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.01934-18

[19] Berthault C, Larcher T, Härtle S, Vautherot J, Trapp-Fragnet L, Denesvre C. Atrophy of primary lymphoid organs induced by Marek’s disease virus during early infection is associated with increased apoptosis, inhibition of cell proliferation and a severe B-lymphopenia. Veterinary Research. 2018. DOI: https://doi.org/10.1186/s13567-018-0526-x

[20] Luo J, Teng M, Zai X, Tang N, Zhang Y, Mandviwala AS, et al.. Efficient Mutagenesis of Marek’s Disease Virus-Encoded microRNAs Using a CRISPR/Cas9-Based Gene Editing System. Viruses. 2020. DOI: https://doi.org/10.3390/v12040466

[21] Sun G, Zhang Y, Zhou L, Lv H, Zhang F, Li K, et al.. Co-Infection with Marek’s Disease Virus and Reticuloendotheliosis Virus Increases Illness Severity and Reduces Marek’s Disease Vaccine Efficacy. Viruses. 2017. DOI: https://doi.org/10.3390/v9060158

[22] Zhang Y, Tang N, Luo J, Teng M, Moffat K, Shen Z, et al.. Marek's Disease Virus-Encoded MicroRNA 155 Ortholog Critical for the Induction of Lymphomas Is Not Essential for the Proliferation of Transformed Cell Lines. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.00713-19

[23] Li H, Zhu J, He M, Luo Q, Liu F, Chen R. Marek’s Disease Virus Activates the PI3K/Akt Pathway Through Interaction of Its Protein Meq With the P85 Subunit of PI3K to Promote Viral Replication. Frontiers in Microbiology. 2018. DOI: https://doi.org/10.3389/fmicb.2018.02547

[24] Tian M, Zhao Y, Lin Y, Zou N, Liu C, Liu P, et al.. Comparative analysis of oncogenic genes revealed unique evolutionary features of field Marek's disease virus prevalent in recent years in China. Virology Journal. 2011. DOI: https://doi.org/10.1186/1743-422X-8-121

[25] Chacón RD, Astolfi-Ferreira C, Guimarães MB, Torres L, Torre DIDl, Sá L, et al.. Detection and Molecular Characterization of a Natural Coinfection of Marek’s Disease Virus and Reticuloendotheliosis Virus in Brazilian Backyard Chicken Flock. Veterinary Sciences. 2019. DOI: https://doi.org/10.3390/vetsci6040092

[26] Liu Y, Gao L, Xu Z, Luo D, Zhang Y, Gao Y, et al.. Marek’s Disease Virus RLORF4 Inhibits Type I Interferon Production by Antagonizing NF-κB Activation. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.01037-19

[27] Neerukonda S, Katneni UK, Bott M, Golovan S, Parcells M. Induction of the unfolded protein response (UPR) during Marek's disease virus (MDV) infection.. Virology. 2018. DOI: https://doi.org/10.1016/j.virol.2018.06.016

[28] Zhou J, Zhao G, Wang X, Du X, Su S, Li C, et al.. Synergistic Viral Replication of Marek’s Disease Virus and Avian Leukosis Virus Subgroup J is Responsible for the Enhanced Pathogenicity in the Superinfection of Chickens. Viruses. 2018. DOI: https://doi.org/10.3390/v10050271

[29] Kennedy DA, Dunn P, Read A. Modeling Marek’s disease virus transmission: A framework for evaluating the impact of farming practices and evolution. Epidemics. 2018. DOI: https://doi.org/10.1016/j.epidem.2018.01.001

[30] Smith J, Lipkin E, Soller M, Fulton J, Burt D. Mapping QTL Associated with Resistance to Avian Oncogenic Marek’s Disease Virus (MDV) Reveals Major Candidate Genes and Variants. bioRxiv. 2020. DOI: https://doi.org/10.3390/genes11091019

[31] Chuard A, Courvoisier-Guyader K, Remy S, Spatz S, Denesvre C, Pasdeloup D. The Tegument Protein pUL47 of Marek’s Disease Virus Is Necessary for Horizontal Transmission and Is Important for Expression of Glycoprotein gC. Journal of Virology. 2020. DOI: https://doi.org/10.1128/JVI.01645-20

[32] Hagag IT, Wight D, Bartsch D, Sid H, Jordan I, Bertzbach LD, et al.. Abrogation of Marek’s disease virus replication using CRISPR/Cas9. Scientific Reports. 2020. DOI: https://doi.org/10.1038/s41598-020-67951-1

[33] Zeng F, Wu M, Ma L, Han Z, Shi Y, Zhang Y, et al.. Rapid and sensitive real-time recombinase polymerase amplification for detection of Marek's disease virus.. Molecular and Cellular Probes. 2019. DOI: https://doi.org/10.1016/j.mcp.2019.101468

[34] Couteaudier M, Denesvre C. Marek’s disease virus and skin interactions. Veterinary Research. 2014. DOI: https://doi.org/10.1186/1297-9716-45-36

[35] Matsuyama-Kato A, Iseki H, Boodhoo N, Bavananthasivam J, Alqazlan N, Abdul-Careem MF, et al.. Phenotypic characterization of gamma delta (γδ) T cells in chickens infected with or vaccinated against Marek's disease virus.. Virology. 2022. DOI: https://doi.org/10.1016/j.virol.2022.01.012

[36] Neerukonda S, Tavlarides-Hontz P, McCarthy F, Pendarvis K, Parcells M. Comparison of the Transcriptomes and Proteomes of Serum Exosomes from Marek’s Disease Virus-Vaccinated and Protected and Lymphoma-Bearing Chickens. Genes. 2019. DOI: https://doi.org/10.3390/genes10020116

[37] Laursen A, Kulkarni R, Taha-Abdelaziz K, Plattner B, Read L, Sharif S. Characterizaton of gamma delta T cells in Marek's disease virus (Gallid herpesvirus 2) infection of chickens.. Virology. 2018. DOI: https://doi.org/10.1016/j.virol.2018.06.014

[38] Stamilla A, Messina A, Condorelli L, Licitra F, Antoci F, Lanza M, et al.. Morphological and Immunohistochemical Examination of Lymphoproliferative Lesions Caused by Marek’s Disease Virus in Breeder Chickens. Animals. 2020. DOI: https://doi.org/10.3390/ani10081280

[39] Bertzbach LD, Haarlem DVv, Härtle S, Kaufer B, Jansen CA. Marek’s Disease Virus Infection of Natural Killer Cells. Microorganisms. 2019. DOI: https://doi.org/10.3390/microorganisms7120588

[40] Bavananthasivam J, Astill J, Matsuyama-Kato A, Taha-Abdelaziz K, Shojadoost B, Sharif S. Gut microbiota is associated with protection against Marek's disease virus infection in chickens.. Virology. 2020. DOI: https://doi.org/10.1016/j.virol.2020.10.011